264208-72-2

Basic information

• Product Name: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
• Synonyms: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline;4-Chloro-7-[N-methylpiperidin-4-ylmethoxy]-6-methoxyquinazoline;4-Chloro-6-Methoxy-7-(4-Methyl-piperidin-1-ylMethoxy)-quinazoline;7-((1-Methylpiperidin-4-yl)Methoxy)-4-chloro-6-Methoxyquinazoline;4-chloro-6-Methoxy-7-[(1-Methyl-4-piperidinyl)Methoxy]-Quinazoline;Quinazoline,4-chloro-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-
• CAS NO: 264208-72-2
• Molecular Formula: C₁₆H₂₀ClN₃O₂
• Molecular Weight: 321.806
• Mol File: 264208-72-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 446.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.221
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.90±0.10(Predicted)
• CAS DataBase Reference: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline(264208-72-2)
• EPA Substance Registry System: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline(264208-72-2)

Safety Data

• Hazardous Substances Data: 264208-72-2(Hazardous Substances Data)

Usage

General Description

4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline is a chemical compound with potential pharmacological properties. It is a quinazoline derivative that has been studied for its potential use in the treatment of various diseases, including cancer and inflammatory conditions. The compound has shown to have inhibitory effects on certain enzymes and receptors in the body, which could make it a valuable candidate for drug development. Additionally, its unique structure and properties make it a promising candidate for further research and potential therapeutic applications.

Upstream product

• 166815-96-9 N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine 
• 338992-29-3 6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one 
• 193002-25-4 7-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one 
• 906565-52-4 methyl 3-methoxy-4-(1-tert-butyloxycarbonylpiperidin-4-ylmethoxy)benzoate 
• 906565-53-5 methyl 5-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-2-nitrobenzoate 
• 635678-10-3 methyl 2-amino-5-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate 
• 635678-09-0 methyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 264208-69-7 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3,4-dihydroxyquinazolin-4-one 
• 20691-89-8 1-methyl-4-piperidinemethanol 
• 263400-68-6 4-chloro-6-methoxy-quinazolin-7-ol 
• 869475-52-5 C₉H₇FN₂O₂ 

Downstream Products

• 320365-81-9 4-(4-bromo-2-fluorophenoxy)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline 
• 1356000-45-7 C₂₉H₃₁FN₆O₃ 
• 1356000-47-9 C₂₉H₃₀F₂N₆O₃ 
• 443913-73-3 vandetanib 

Relevant articles and documents

QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF

Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the compound of formula (I

Anilinoquinazoline inhibitors of the RET kinase domain - Elaboration of the 7-position

We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physicochemical properties, delivering improvements in cell potency. However, whilst cellular selectivity against key targets could be maintained, combining cell potency and acceptable pharmacokinetics proved challenging.

A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines

A novel strategy to prepare 4-anilinoquinazoline derivatives based on the oxidation of the quinazoline ring is described. Quinazoline oxidation has been investigated and improved, thus leading to an efficient and high yielding method to quinazolin-4(3H)-ones. Efficiency of this approach has been evaluated synthesizing four well known tyrosine kinase inhibitors and comparing the obtained yields with those achievable through conventional synthetic methods.